ORBIMED ADVISORS LLC 13D and 13G filings for Crinetics Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 6:36 pm Sale | 2023-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX | ORBIMED ADVISORS LLC | 1,667,360 2.500% | -1,529,516 (-47.84%) | Filing |
| 2023-02-14 4:12 pm Unchanged | 2022-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX | ORBIMED ADVISORS LLC | 3,196,876 5.900% | 0 (Unchanged) | Filing |
| 2022-02-11 4:19 pm Purchase | 2021-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX | ORBIMED ADVISORS LLC | 3,196,876 6.700% | 443,309 (+16.10%) | Filing |
| 2021-02-12 4:44 pm Purchase | 2020-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX | ORBIMED ADVISORS LLC | 2,753,567 8.360% | 714,285 (+35.03%) | Filing |